ENTA
NASDAQ HealthcareEnanta Pharmaceuticals, Inc. - Common Stock
Biotechnology
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for virology and immunology indications. The company's product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; zelicapavir and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; EDP-978 for chronic spontaneous urticaria (CSU); Glecaprevir, antiviral protease inhibitors for the treatment of chronic infection with hepatitis C virus or HCV; and EPS-3903 for the treatment of atopic dermatitis. It has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. The company was incorporated in 1995 and is headquartered in Watertown, Massachusetts.
�� 市场数据
| 价格 | $12.03 |
|---|---|
| 成交量 | 196,226 |
| 市值 | 349.81M |
| 贝塔系数 | 1.010 |
| RSI（14日） | 18.4 超卖 |
| 200日均线 | $12.51 |
| 50日均线 | $13.63 |
| 52周最高 | $17.15 |
| 52周最低 | $6.38 |
| Forward P/E | -6.15 |
| Price / Book | 3.00 |
🎯 投资策略评分
ENTA 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (90/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🎈 Over-Hyped (1/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 ENTA in your text
粘贴任何文章、记录或帖子 — 工具将提取 ENTA 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-06-02.